Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
October 02 2018 - 4:05PM
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that
two abstracts – one addressing clinical results with the company’s
pan-caspase inhibitor, emricasan, and one addressing preclinical
results with the company’s pan-caspase inhibitor, IDN-7314 – have
been accepted for oral presentations; and one abstract addressing
preclinical results with emricasan has been accepted for a poster
presentation at The Liver Meeting®, the annual meeting of the
American Association for the Study of Liver Diseases (AASLD) in San
Francisco November 9-13, 2018. Accepted abstracts were published
yesterday on the Hepatology website1.
Abstracts accepted for oral presentations included:
- “Multicenter, double-blind, randomized trial of emricasan in
subjects post liver transplantation (LT) with recurrent hepatitis C
virus (HCV) and liver fibrosis or cirrhosis despite achieving
sustained virologic response (SVR),” (abstract #1226, originally
accepted as poster, later accepted as oral presentation); and
- “Intestinal dysbiosis augments liver disease progression via
NLRP3 in a murine model of primary sclerosing cholangitis,”
(abstract #25);
and abstracts accepted for posters included:
- “Molecular mechanisms underlying the effects of emricasan in
portal hypertension and chronic liver disease: the
hepato-sinusoidal cross-talk matters,” (abstract #1344).
Abstract #25 is an AASLD Foundation Abstract Award Recipient and
was accepted for presentation in the Presidential Plenary Session
on Translational Science and Genomics.
“As we advance toward releasing top-line results over the next
15 months from our three ENCORE Phase 2b clinical trials in
patients with nonalcoholic steatohepatitis (NASH), the body of
preclinical and clinical data documenting the activity and effects
of pan-caspase inhibitors continues to grow,” said Conatus
co-founder, President and Chief Executive Officer Steven J. Mento,
Ph.D. “Thanks to the work of our principal investigators and our
scientific collaborators, we have an ever-deepening understanding
of the multiple mechanistic effects of caspase inhibitors on liver
structure and function, as well as their disease-modifying
potential. We are pleased with the recognition afforded to these
latest developments at the upcoming AASLD meeting.”
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development of novel medicines
to treat liver disease. In collaboration with Novartis, Conatus is
developing its lead compound, emricasan, for the treatment of
patients with chronic liver disease. Emricasan is a first-in-class,
orally active pan-caspase inhibitor designed to reduce the activity
of enzymes that mediate inflammation and apoptosis. Conatus
believes that by reducing the activity of these enzymes, caspase
inhibitors have the potential to interrupt the progression of a
variety of diseases. For additional information, please visit
www.conatuspharma.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward-looking statements, including
statements regarding: the timeline for results from the
ENCORE trials; and caspase inhibitors’ potential to modify disease
and interrupt the progression of a variety of diseases. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including: the risk that the preclinical results may not be
predictive of future clinical trial results; and those risks
described in the company’s prior press releases and in the periodic
reports it files with the Securities and Exchange Commission. The
events and circumstances reflected in the company’s forward-looking
statements may not be achieved or occur and actual results could
differ materially from those projected in the forward-looking
statements. Except as required by applicable law, the company does
not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
1 Hepatology 68:S1 (October 2018)
https://aasldpubs.onlinelibrary.wiley.com/journal/15273350.
CONTACT: Alan EngbringConatus
Pharmaceuticals Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2024 to May 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From May 2023 to May 2024